CONMED Q3: Strong Results & New Share Repurchase
Update: 2025-11-06
Description
CONMED, a medical technology company, reported robust third-quarter results for 2025, surpassing Wall Streets expectations with revenues of $337.9 million, a 6.7% increase from the previous year. Their non-GAAP profit per share also exceeded estimates. CONMED raised its full-year revenue and adjusted earnings per share guidance, driven by strong sales of core products like BioBrace and AirSeal platform. The companys growth was attributed to improved supply chain operations, clinical adoption, and surgeon engagement. CONMED plans to focus on product portfolio and operational discipline, with a new $150 million share repurchase authorization, suspending its dividend program to enhance financial flexibility.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
